Infectious Disease Experts Recommend Using Antibodies from COVID-19 Survivors as Stopgap Measure to Treat Patients and Protect Healthcare Workers

INFUSIONS OF ANTIBODY-LADEN BLOOD HAVE BEEN USED WITH REPORTED SUCCESS IN PRIOR OUTBREAKS, INCLUDING THE SARS EPIDEMIC AND THE 1918 FLU PANDEMIC Countries fighting outbreaks of the novel coronavirus disease COVID-19 should consider using the antibodies of people who have recovered from infection to treat cases and provide short-term immunity—lasting weeks to months—to critical health care

Read More


Pluristem and Charité University of Medicine Berlin Join Forces Targeting Potential Treatment for Respiratory and Inflammatory Intratissue Complications Caused by COVID-19

 Pluristem Therapeutics Inc., a leading regenerative medicine company developing a platform of novel biological products, today announced it has signed a collaborative agreement with the BIH Center for Regenerative Therapy (BCRT) and the Berlin Center for Advanced Therapies (BeCAT) at Charite’ University of Medicine Berlin to expand its existing framework and research agreement and conduct

Read More